- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
		
	   		
	   		    
                    
                   	
                   	    8 result(s) found for: Tensin.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2008-003988-39 | Sponsor Protocol Number: VA 2008/34 | Start Date*: 2008-11-19 | |||||||||||
| Sponsor Name:Centre Régional de Lutte contre le Cancer Val d'Aurelle- Paul Lamarque | |||||||||||||
| Full Title: Essai de phase I-II évaluant l’association de Cetuximab et de Trastuzumab chez des patients atteints de cancer pancréatique métastatique ayant progressé sous chimiothérapie à base de gemcitabine (E... | |||||||||||||
| Medical condition: Adénocarcinome pancréatique métastatique histologiquement confirmé en progression et ayant reçu une chimiothérapie à base de Gemcitabine. | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002637-11 | Sponsor Protocol Number: CBYL719H12301 | Start Date*: 2020-03-18 | 
| Sponsor Name:Novartis Pharma AG | ||
| Full Title: EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with adv... | ||
| Medical condition: Advanced triple negative breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) FR (Completed) SK (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) NO (Completed) AT (Completed) BG (Completed) SI (Completed) PL (Completed) HR (Completed) GR (Completed) RO (Completed) PT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-004429-17 | Sponsor Protocol Number: CO39303 | Start Date*: 2018-09-19 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/... | |||||||||||||
| Medical condition: Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: NO (Completed) PT (Completed) DE (Completed) DK (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) BE (Completed) ES (Ongoing) GR (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-016875-30 | Sponsor Protocol Number: VA 2009/40 | Start Date*: 2010-04-12 | |||||||||||
| Sponsor Name:CRLC VAL D’AURELLE | |||||||||||||
| Full Title: Essai de phase II évaluant l’association de gemcitabine, trastuzumab et erlotinib en 1ère ligne de traitement par chimiothérapie des patients atteints d’un adénocarcinome du pancréas métastatique | |||||||||||||
| Medical condition: adénocarcinome du pancréas métastatique | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000346-33 | Sponsor Protocol Number: D361BC00001 | Start Date*: 2020-07-20 | 
| Sponsor Name:AstraZeneca AB | ||
| Full Title: Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic Ho... | ||
| Medical condition: Metastatic Hormone-Sensitive Prostate Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: NL (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) SK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004648-44 | Sponsor Protocol Number: MedOPP253 | Start Date*: 2020-07-06 | ||||||||||||||||||||||||||
| Sponsor Name:Medica Scientia Innovation Research S.L (MEDSIR) | ||||||||||||||||||||||||||||
| Full Title: A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pre... | ||||||||||||||||||||||||||||
| Medical condition: UNRESECTABLE LOCALLY ADVANCED OR METASTATIC RIPLE-NEGATIVE BREAST CANCER PATIENTS | ||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: PT (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2022-001398-30 | Sponsor Protocol Number: MEDOPP437 | Start Date*: 2023-05-08 | 
| Sponsor Name:Medica Scientia Innovation Research, S.L. | ||
| Full Title: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 M... | ||
| Medical condition: Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolo... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-004977-23 | Sponsor Protocol Number: DP312804 | Start Date*: 2013-04-25 | |||||||||||
| Sponsor Name:SFJ LungCancer, Ltd. | |||||||||||||
| Full Title: ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF 00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL CELL... | |||||||||||||
| Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) IT (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
